Neurology

Research may address the lack of effective treatments for mental fatigue among patients with multiple sclerosis.

Spinal muscular atrophy is the leading genetic cause of death in infants.

The combination medication is used to treat the symptoms of tension or muscle contraction headaches. The drug is only available via a prescription from a physician.

New molecules could the brain’s immune system to better control epilepsy.

Tofersen proves safe in clinical trials in the treatment of amyotrophic lateral sclerosis.

The study concluded that pharmacists reportedly scored higher on the knowledge test than neurologists and nurse practitioners.

Regardless of the channel through which a specialty medication is billed and filled, management strategies will be an essential cornerstone to controlling costs.

Low back pain is one of the leading reasons people seek medical care and the number 1 cause of disability globally.

The key to better outcomes for patients with MS is to address it early.

According to a recent study published in Gut, inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn disease, is associated with a more than doubled likelihood of developing dementia.

Dravet syndrome is a life-threatening, rare, and chronic form of epilepsy and is often characterized by severe, unrelenting seizures despite medical treatment, according to the FDA press release.

Cognitive impairment is extremely common among patients with MS, affecting approximately two-thirds of this patient population.

The NIA is currently funding more than 230 active clinical trials on AD and related dementias. Of those, more than 100 are nondrug interventions, such as exercise, diet, cognitive training, sleep, or combination therapies.

After up to 4.8 years of treatment with nusinersen, 100% of children with spinal muscular atrophy (SMA) who were treated pre-symptomatically are still alive.

The researchers identified 87 articles using the PubMed and PsycINFO databases and the 2017 American Academy of Neurology (AAN) criteria for therapeutic trials.

The authors posited that teriflunomide could prevent an excessive immune response while still maintaining enough defense against the virus.

SE requires prompt intervention to terminate seizure activity to prevent neuronal damage and complications.

Galcanezumab-gnlm (Emgality, Lilly) has received FDA-approval for the preventive treatment of migraine in adults and for the treatment of episodic cluster headache in adults.

As Alzheimer disease research evolves beyond targeting a single pathology, interventions should coordinate disease stage with pathology and the patient’s presenting characteristics.

According to a recent study, people with a higher risk of cardiovascular disease demonstrate an increase in cognitive decline, including a rise in the typical markers of Alzheimer disease.

New treatment options offer hopes of better clinical outcomes for patients suffering from Parkinson disease and its debilitating daily symptoms.

Dihydroergotamine Mesylate Nasal Spray is FDA-approved as therapeutic equivalent to Migranal.

Telemedicine and connected devices are emerging as technologies to provide greater access and convenience to care for those who can defer treatment by way of an in-person consultation.

The recommended dosage of lemborexant CIV is one 5 mg tablet taken no more than once per night, immediately before going to bed with at least 7 hours remaining before the planned time of awakening.

Ensuring patients continue receiving life-sustaining home infusions that were traditionally administered in the hospital or hospital clinic settings is of the upmost importance.

Officials from the FDA have approved flortaucipir F18 (Tauvid, Eli Lilly) for intravenous injection as the first drug used to help image a distinctive characteristic of Alzheimer disease in the brain called tau pathology.

Despite triptan availability as a migraine-specific rescue, the global burden of migraine morbidity remains high.

The FDA approval of solifenacin succinate marks the first for the treatment of young pediatric patients with NDO.

Officials with the FDA have approved apomorphine hydrochloride sublingual film (APL-130277) for the acute, intermittent treatment of OFF episodes in patients with Parkinson disease.

According to the study authors, patients with MS who underwent the 4-week mindfulness training not only showed greater improvement in processing speed and regulating negative emotions than those who did not participate in any training, but they also improved compared with those who tried adaptive cognitive training (ACT).